Medtronic‘s (NYSE:MDT) Canada subsidiary said today that it won a license from Health Canada for its MiniMed 670G insulin pump system.
The insulin pump system is the first device in Canada that stabilizes glucose levels by automatically adjusting basal insulin delivery according to a user’s real-time needs, the medtech titan touted.
Medtronic expects to launch its MiniMed 670G system in Canada sometime in the fall of 2018. The company noted that the system is specifically licensed for use in people with Type 1 diabetes ages seven and older.
“We are very pleased to bring the MiniMed 670G insulin pump system to Canada this fall,” Laura Cameron, senior director of the diabetes group at Medtronic Canada, said in prepared remarks. “For more than 30 years Medtronic has been serving and supporting the Diabetes community. The long-standing collaboration and insights from many health care professionals and patient groups has contributed to this milestone in the evolution of insulin delivery — the world’s first self-adjusting insulin pump system. We are grateful for the opportunity to provide this latest innovation in diabetes management to Canadians, and remain committed to helping make patient’s lives a little easier.”
“The MiniMed 670G system with SmartGuard hybrid closed loop algorithm is the first and only insulin pump system that constantly self-adjusts basal insulin. It answers many of the current challenges in managing Type 1 diabetes by minimizing blood glucose variability and maximizing time in target range,” Dr. Robyn Houlden, chair of the 2018 Diabetes Canada Clinical Practice Guidelines, added. “It will usher in a new era in diabetes management that empowers patients to confidently optimize their blood glucose control.”
